貨號：GS40203

Ebronucimab (AK102) is a fully human IgG1 monoclonal antibody developed to lower low-density lipoprotein cholesterol (LDL-C) by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). It is designed as a therapeutic for the management of hypercholesterolemia and the reduction of cardiovascular risk, particularly in patients who require additional LDL-C lowering beyond statin therapy or who are statin-intolerant. By inhibiting PCSK9, ebronucimab increases the availability of hepatic LDL receptors, leading to enhanced clearance of LDL particles from the bloodstream.